REVENUE

12 Months Ended

Dec. 31, 2022

REVENUE

REVENUE

NOTE 8 - REVENUE

The following table summarizes the Company’s disaggregation of revenues:

	Year Ended December 31,
(U.S. dollars in thousands)	2020		2021		2022
Pfizer	$	8,105	$	10,160	$	12,403
Brazil	$	8,000	$	6,400	$	9,452
Chiesi		131	$	189	$	3,437
Total revenues from selling goods	$	16,236	$	16,749	$	25,292
Revenues from license and R&D services	$	46,662	$	21,601	$	22,346

During the year ended December 31, 2021, and following the CRL received from the FDA and other understandings with Chiesi, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in reduced revenues recognized in respect of this performance obligation in 2021.